ATHA
NASDAQAthira Pharma Inc.
Price$6.87+3.00 (+77.29%)
2025-10-072026-01-09
News · 26 weeks230%
2025-11-022026-04-26
Mix090d
No activity.
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.SCHEDULE 13D/A - LeonaBio, Inc. (0001620463) (Subject)
- SECAthira Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Leadership Update, Financial Statements and Exhibits8-K - LeonaBio, Inc. (0001620463) (Filer)
- PRAthira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA"BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company's transformative acquisition of rights to develop and commercialize lasofoxifene, a promising late-stage clinical asset for the potential treatment of metastatic breast cancer, currently in a Phase 3 trial (NCT05696626). In connection with the name change, the Company will change its ticker symbol to "LONA." The Company's common stock will commence trading on The Nasdaq
- INSIDERCHIEF MEDICAL OFFICER San Martin Javier converted options into 4,667 shares and sold $11,311 worth of shares (1,644 units at $6.88), increasing direct ownership by 42% to 10,189 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERPresident and CEO Litton Mark James sold $17,792 worth of shares (2,586 units at $6.88) and converted options into 10,834 shares, increasing direct ownership by 25% to 40,828 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERChief Financial Officer Renninger Robert was granted 1,000 shares, converted options into 1,236 shares and sold $2,043 worth of shares (297 units at $6.88), increasing direct ownership by 18% to 12,857 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Church Kevin was granted 1,000 shares, converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 22% to 20,681 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERGeneral Counsel and CCO Worthington Mark converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 25% to 13,978 units (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Renninger Robert4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Litton Mark James4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier4 - Athira Pharma, Inc. (0001620463) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel and CCO Worthington Mark4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.SCHEDULE 13D/A - Athira Pharma, Inc. (0001620463) (Subject)
- INSIDERDirector Perceptive Advisors Llc was granted 1,319,026 shares (SEC Form 4)4 - Athira Pharma, Inc. (0001620463) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.SCHEDULE 13D/A - Athira Pharma, Inc. (0001620463) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Athira Pharma Inc.SCHEDULE 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
- SECAmendment: Athira Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K/A - Athira Pharma, Inc. (0001620463) (Filer)
- SECAthira Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Athira Pharma, Inc. (0001620463) (Filer)
- PRAthira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 MillionPhase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, today announced that it has entered into an agreement to acquire the right
- SECSEC Form 10-Q filed by Athira Pharma Inc.10-Q - Athira Pharma, Inc. (0001620463) (Filer)
- SECAthira Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Athira Pharma, Inc. (0001620463) (Filer)
- PRAthira Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdateContinuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as well as dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development BOTHELL, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2025, and provided recent business updates. "We continue to explore
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Athira Pharma Inc.SCHEDULE 13G/A - Athira Pharma, Inc. (0001620463) (Subject)
- SECAthira Pharma Inc. filed SEC Form 8-K: Other Events8-K - Athira Pharma, Inc. (0001620463) (Filer)
ATHA FAQ
7 questionsWhat does Athira Pharma Inc. do?
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric...Where does ATHA stock trade?
Athira Pharma Inc. (ATHA) is listed on NASDAQ.What sector and industry is ATHA in?
Athira Pharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Athira Pharma Inc. go public?
Athira Pharma Inc. (ATHA) completed its IPO in 2020.What are analysts saying about ATHA?
Athira Pharma Inc. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Neutral with a $50.00 price target on 2024-09-19.What companies are similar to ATHA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ATHA side-by-side with any of them on Quantisnow.How can I track ATHA on Quantisnow?
Quantisnow aggregates Athira Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATHA to receive live email and push alerts on every new disclosure.